Julia E. Wiedmeier, DL Riggs, CK Stein, Kiran K. Mangalaparthi, Richard K. Kandasamy, S. Brown, K. Franke, Y. Shotts, JC Figueroa Aguirre, Yan W. Asmann, Esteban Braggio, R. Fonseca, Akhilesh Pandey, Marta Chesi, P. Leif Bergsagel
Abstract Multiple myeloma (MM) is an incurable plasma cell neoplasm characterized by diverse and complex genetic abnormalities, including translocations of immunoglobulin (Ig) genes and a hyperdiploid karyotype. Much of our current understanding of MM genetics, epigenetics, pathogenesis and response/resistance to myeloma directed therapies originated from studies on human MM-derived cell lines (HMCL). In this study, we conducted an integrated multi-omics analysis in five hyperdiploid cell lines established from serial samples from a single relapsed/refractory hyperdiploid MM patient, enabling detailed characterization of the genetic landscape and molecular alterations through disease progression.